Investigational micro-implant is being designed to deliver localized bioelectric signaling in support of retinal, optic-nerve and aqueous-outflow health
HUNTINGTON BEACH, Calif. — August 27, 2026 — Lionheart Health, Inc. announced that its E‑Stent™ bioelectric stimulation platform, previously introduced for regenerative medicine applications throughout the body, is being adapted for investigational use in vision regeneration and the treatment of eye-pressure-related ailments.
The original E‑Stent™ platform combines a miniature implant containing embedded micro-coils or electrodes with an externally worn wireless controller. The system is designed to deliver precisely controlled bioelectric signals directly to targeted tissues. E‑Stent™ devices may range from micro-implants smaller than a pea to larger vascular stents, depending on the intended application.
For ophthalmic development, Lionheart Health is evaluating a miniature Eye E‑Stent™ configuration intended to support two major objectives:
- Vision regeneration research focused on retinal health, optic-nerve protection, improved microcirculation, inflammation management and activation of the body’s natural repair pathways.
- Eye-pressure management research focused on supporting aqueous-humor drainage, tissue elasticity and healthier function of the eye’s natural outflow structures—areas associated with ocular hypertension and glaucoma.
The development program will evaluate localized bioelectric signaling sequences intended to influence biological pathways associated with neuroprotection, circulation, extracellular-matrix remodeling, inflammation control, cellular recruitment and tissue repair. The company also plans to study whether the technology can complement Lionheart’s existing EyeCell™ platform and other noninvasive modalities, including externally applied bioelectric stimulation, photobiomodulation and regenerative biologics.
“Eye pressure and progressive vision loss remain among the most serious unmet challenges in medicine,” said Howard J. Leonhardt, Executive Chairman and Co‑CEO of Lionheart Health and founder of Leonhardt Ventures. “Our goal is to adapt the E‑Stent platform so that precisely controlled regenerative signals may be delivered exactly where they are needed—potentially supporting healthier fluid outflow while also protecting and regenerating the tissues responsible for vision.”
The ophthalmic E‑Stent concept may be engineered for placement near an appropriate eye drainage structure or other targeted tissue, subject to anatomical, engineering, safety and regulatory review. Potential future versions may incorporate pressure sensing and feedback-controlled stimulation, creating a closed-loop system capable of adjusting therapy in response to measured conditions.
Lionheart believes the program could eventually address several related areas of research, including:
- Ocular hypertension and elevated intraocular pressure
- Glaucoma-related optic-nerve injury
- Reduced ocular microcirculation
- Retinal and optic-nerve degeneration
- Inflammation and fibrosis affecting aqueous outflow
- Recovery support following selected ophthalmic procedures
The company plans to proceed through engineering development, benchtop validation, preclinical testing and properly authorized clinical research. Lionheart Health will also evaluate additional intellectual-property filings covering the ophthalmic configuration, placement methods, stimulation sequences, sensing capabilities and combination protocols.
About Lionheart Health
Lionheart Health, Inc. is a healthspan and regenerative-medicine company developing bioelectric stimulation technologies, wearable devices, implantable systems and combination biologic protocols. Its development portfolio includes programs addressing brain, muscle, immune, cardiovascular, joint, kidney, skin, hair, sexual, bladder and vision health.
The company’s broader technology platform is designed to combine precision bioelectric signaling with regenerative-support modalities, including stem cells, exosomes, peptides, growth factors, platelet-rich fibrin and nutrient-engineered hydrogels.
Forward-Looking and Regulatory Statement
The ophthalmic E‑Stent™, EyeCell™ and the vision-regeneration applications described in this release are investigational. They have not been cleared or approved by the U.S. Food and Drug Administration to regenerate vision, treat glaucoma, reduce intraocular pressure or treat any other eye disease. References to possible mechanisms, benefits and future applications represent research objectives and development hypotheses, not established clinical outcomes. Any clinical use will require appropriate regulatory authorization, institutional review and qualified medical supervision.
Media and Partnership Contact
Lionheart Health, Inc.
Huntington Beach, California